147References
Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B1502 screening in
Taiwan. N Engl J Med. 2011;364:1126–33.
Csoka AB, Szyf M. Epigenetic side-effects of common pharmaceuticals: a potential new fi eld in
medicine and pharmacology. Med Hypotheses. 2009;73:770–80.
Damani SB, Topol EJ. The case for routine genotyping in dual-antiplatelet therapy. J Am Coll
Cardiol. 2010;56:109–11.
Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inade-
quate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009;10:1799–817.
Ford NF. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol.
2009;49:506–12.
Frueh FW, Amur S, Mummaneni P, et al. Pharmacogenomic biomarker information in drug labels
approved by the United States food and drug administration: prevalence of related drug use.
Pharmacotherapy. 2008;28:992–8.
Giorgi MA, Caroli C, Arazi HC, Di Girolamo G. Pharmacogenomics and adverse drug reactions:
the case of statins. Expert Opin Pharmacother. 2011;12:1499–509.
Goldstein JI, Fredrik Jarskog L, Hilliard C, et al. Clozapine-induced agranulocytosis is associated
with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014;5:4757.
Holmes Jr DR, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the
FDA “Boxed Warning”. J Am Coll Cardiol. 2010;56:321–41.
Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function,
and cardiovascular events. a systematic review and meta-analysis. JAMA. 2011;306:2704–14.
Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reac-
tions. N Engl J Med. 2008;358:637–9.
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Infl uence of cytochrome P450
polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Pharmacol Ther. 2007;116:496–526.
Jain KK. Biomarkers: technologies, markets and companies. Basel: Jain Pharma Biotech; 2015.
Lee MT, Hung SI, Wei CY, Chen YT. Pharmacogenetics of toxic epidermal necrolysis. Expert Opin
Pharmacother. 2010;11:2153–62.
Lee SJ. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine.
Front Genet. 2013;3:318.
Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopido-
grel. N Engl J Med. 2009;360:354–62.
McCormack M, Alfi revic A, Bourgeois S, et al. HLA-A3101 and carbamazepine-induced hyper-
sensitivity reactions in Europeans. N Engl J Med. 2011;364:1134–43.
Momary KM, Dorsch MP, Bates ER. Genetic causes of clopidogrel nonresponsiveness: which
ones really count? Pharmacotherapy. 2010;30:265–74.
Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in
women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the
Justifi cation for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin
(JUPITER) and meta-analysis of women from primary prevention trials. Circulation.
2010;121:1069–77.
Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treat-
ment. N Engl J Med. 2010;363:1704–14.
Pereira CV, Moreira AC, Pereira SP, et al. Investigating drug-induced mitochondrial toxicity: a
biosensor to increase drug safety? Curr Drug Saf. 2009;4:34–54.
Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of
warfarin. N Engl J Med. 2013;369:2294–303.
Ray LA, Miranda Jr R, MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse
events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17:122–9.